Monitoring Cannabinoid CB2 -Receptor Mediated cAMP Dynamics by FRET-Based Live Cell Imaging.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Oct 2020
Historique:
received: 22 09 2020
revised: 17 10 2020
accepted: 19 10 2020
entrez: 29 10 2020
pubmed: 30 10 2020
medline: 2 3 2021
Statut: epublish

Résumé

G-protein coupled cannabinoid CB2 receptor signaling and function is primarily mediated by its inhibitory effect on adenylate cyclase. The visualization and monitoring of agonist dependent dynamic 3',5'-cyclic adenosine monophosphate (cAMP) signaling at the single cell level is still missing for CB2 receptors. This paper presents an application of a live cell imaging while using a Förster resonance energy transfer (FRET)-based biosensor, Epac1-camps, for quantification of cAMP. We established HEK293 cells stably co-expressing human CB2 and Epac1-camps and quantified cAMP responses upon Forskolin pre-stimulation, followed by treatment with the CB2 ligands JWH-133, HU308, β-caryophyllene, or 2-arachidonoylglycerol. We could identify cells showing either an agonist dependent CB2-response as expected, cells displaying no response, and cells with constitutive receptor activity. In Epac1-CB2-HEK293 responder cells, the terpenoid β-caryophyllene significantly modified the cAMP response through CB2. For all of the tested ligands, a relatively high proportion of cells with constitutively active CB2 receptors was identified. Our method enabled the visualization of intracellular dynamic cAMP responses to the stimuli at single cell level, providing insights into the nature of heterologous CB2 expression systems that contributes to the understanding of Gαi-mediated G-Protein coupled receptor (GPCR) signaling in living cells and opens up possibilities for future investigations of endogenous CB2 responses.

Identifiants

pubmed: 33114208
pii: ijms21217880
doi: 10.3390/ijms21217880
pmc: PMC7660676
pii:
doi:

Substances chimiques

Arachidonic Acids 0
Cannabinoids 0
Endocannabinoids 0
Glycerides 0
Guanine Nucleotide Exchange Factors 0
Polycyclic Sesquiterpenes 0
RAPGEF3 protein, human 0
Receptor, Cannabinoid, CB2 0
Colforsin 1F7A44V6OU
glyceryl 2-arachidonate 8D239QDW64
HU 308 8I5L034D55
caryophyllene BHW853AU9H
Cyclic AMP E0399OZS9N
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC TDG8048RDA

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Br J Pharmacol. 2011 Aug;163(7):1432-40
pubmed: 21457226
J Pharmacol Exp Ther. 2016 Aug;358(2):342-51
pubmed: 27194477
Biochem Pharmacol. 2016 Jan 1;99:60-72
pubmed: 26410677
Nat Protoc. 2011 Apr;6(4):427-38
pubmed: 21412271
Br J Pharmacol. 2006 Jan;147 Suppl 1:S27-37
pubmed: 16402114
J Biol Chem. 2004 Sep 3;279(36):37215-8
pubmed: 15231839
J Biol Chem. 2009 Dec 18;284(51):35450-60
pubmed: 19858202
Cancer Res. 2008 Jan 15;68(2):339-42
pubmed: 18199524
Front Pharmacol. 2020 Mar 25;11:359
pubmed: 32269529
Adv Pharmacol. 2017;80:329-366
pubmed: 28826540
ACS Pharmacol Transl Sci. 2019 Oct 01;2(6):414-428
pubmed: 32259074
Nat Methods. 2008 Jan;5(1):29-36
pubmed: 18165805
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
Physiology (Bethesda). 2006 Apr;21:86-92
pubmed: 16565474
PLoS One. 2011 Apr 29;6(4):e19170
pubmed: 21559477
Front Pharmacol. 2019 Apr 05;10:339
pubmed: 31024307
J Vis Exp. 2012 Aug 20;(66):e4081
pubmed: 22929080
Nat Rev Neurol. 2020 Jan;16(1):9-29
pubmed: 31831863
Br J Pharmacol. 2012 Apr;165(8):2561-74
pubmed: 21615724
Nature. 1997 Aug 21;388(6644):773-8
pubmed: 9285589
Methods Mol Biol. 2017;1563:85-90
pubmed: 28324603
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Endocr J. 2016 Jun 30;63(6):507-14
pubmed: 26961122
Cell Cycle. 2014;13(9):1400-12
pubmed: 24626186
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):165-176
pubmed: 31559333
Pflugers Arch. 2017 Jun;469(5-6):725-737
pubmed: 28386636
Cell Mol Neurobiol. 2003 Jun;23(3):305-14
pubmed: 12825829
Methods Enzymol. 2017;593:43-59
pubmed: 28750814
Front Pharmacol. 2015 Aug 25;6:172
pubmed: 26379548
Int J Mol Sci. 2017 Apr 01;18(4):
pubmed: 28368293
Br J Pharmacol. 2009 Sep;158(1):382-91
pubmed: 19552692
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9099-104
pubmed: 18574142
Cancer Med. 2018 Mar;7(3):765-775
pubmed: 29473338
J Biol Chem. 2010 May 14;285(20):14990-8
pubmed: 20299453
Mol Pharmacol. 1999 Mar;55(3):473-80
pubmed: 10051530
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Commun. 2017 Jan 03;8:13958
pubmed: 28045021
Elife. 2016 Mar 22;5:
pubmed: 27003291
Front Mol Neurosci. 2019 Sep 20;12:224
pubmed: 31616248
PeerJ. 2019 Sep 25;7:e7733
pubmed: 31579608
PLoS One. 2014 Sep 09;9(9):e106608
pubmed: 25203113

Auteurs

Leonore Mensching (L)

Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany.

Sebastian Rading (S)

Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany.

Viacheslav Nikolaev (V)

Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany.
DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Martinistr. 52, D-20246 Hamburg, Germany.

Meliha Karsak (M)

Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH